Clinical response to FGFR inhibitors in patients with FGFR2-amplified advanced gastric cancer: two case reports - Takeaways - MDSpire

Clinical response to FGFR inhibitors in patients with FGFR2-amplified advanced gastric cancer: two case reports

  • By

  • Jing-Jing Li

  • Yu- Qian

  • Hui-Ting Xu

  • Yan-Li Nie

  • July 7, 2026

  • 0 min

Share

  • 1

    FGFR2 amplification in gastric cancer is associated with significantly worse survival compared to FGFR2-unamplified cases.

  • 2

    Two cases of advanced gastric cancer with FGFR2 amplification were treated with FGFR inhibitors, showing varying progression-free and overall survival.

  • 3

    The first patient achieved a progression-free survival of 4.4 months and overall survival of 8.3 months with pemigatinib.

  • 4

    The second patient attained a progression-free survival of 5.7 months and overall survival of 18.5 months with infigratinib.

  • 5

    Both patients experienced manageable adverse events related to FGFR inhibitors, highlighting their potential in chemotherapy-intolerant cases.

Original Source(s)

Clinical response to FGFR inhibitors in patients with FGFR2-amplified advanced gastric cancer: two case reports

  • by Jing-Jing Li, Yu- Qian, Hui-Ting Xu, Yan-Li Nie

  • July 7, 2026

Related Content

AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications

Developing a predictive model for early urinary incontinence after laparoscopic radical prostatectomy: a retrospective cohort study